Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects achieving a response who receive rusfertide compared to placebo. Description: Response is defined as absence of phlebotomy eligibility. Time frame: Week 20 through Week 32. After: Measure: Part 1a: Percentage of Participants Who Achieved Response Description: Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%. Time frame: From Weeks 20 to 32.